EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Ad-hoc: Relief Therapeutics Holding SA / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment 16-Feb-2022 / 07:00 CET/CEST Release of an a...
Source: boersennews.de